Catalyst Wire Dossier Catalyst Wire Dossier

ARX-F03 Sublingual Sufentanil/Triazolam NanoTab

sufentanil/triazolam · Talphera, Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARX-F03 Sublingual Sufentanil/Triazolam NanoTab, covering 2014-06-25 to 2014-06-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure [Phase 2]

See pricing